- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeremy Schafer Discusses the Importance of Immunogenicity of Biosimilars
The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
Transcript (slightly modified)
What is the most recent data on the immunogenicity of biosimilars?
I think the most recent data that will resonate most with this audience, that they’re paying the most attention to, is going to be the biosimilar infliximab that the FDA recently approved. And, in that data they found from a immunogenicity profile that it is more or less similar, and that’s going to be a very important component for any biosimilar manufacturer because I think that a lot of payers and providers are going to assume that yeah the efficacy is probably pretty similar and safety, sure, but immunogenicity: is there going to be differences? Because maybe the manufacturing was a little bit different, or some of the inert ingredients are a little bit different, and particularly if we’re thinking of changing patients from the brand to the biosimilar then immunogenicity is really going to matter.
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More
